CXCR4 and glioblastoma: We demonstrated that the polyphemusin II-derived peptidomimetic POL3026 and its PEGylated analog have suitable pharmacokinetics for non-invasive detection of CXCR4 expression in a U87-stb-CXCR4 glioblastoma mouse model [28].